Looking for the Next "PSA"
Cancer diagnostics has been a tough field for companies. But the need for good tests remains, and with new technologies being discovered, the opportunities still seem worth pursuing. Witness the deals signed in the field in the past half year. While none are large, they address either diagnostic companies' search for growth and high value, proprietary tests, or biotech companies' desire to foster basic research for pharmaceutical products or evaluate therapeutic impact on specific patients.
You may also be interested in...
Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.
Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.
Pacific Biosciences of California and Aziyo Biologics both acquire new finance chiefs; Illumina hires a new chief marketing officer; WishBone Medical president moves over to take helm at Electromedical Products International; and more.